APAC Veterinary Vaccines Market Size & Growth Rate (2019 - 2024)
The Asia-Pacific animal vaccines market is poised to reach USD 1.53 Billion by 2024 from USD 1.08 Billion in 2019, at a CAGR of 7.22% from 2019 - 2024 and considered as the fastest-growing region in the global veterinary vaccines market.
It has seen significant growth over the past few years, due to fear of imminent epidemics that have led to substantial losses, particularly in the poultry segment. The veterinary vaccine market’s substantial growth can be attributed to increasing husbandry practices and better management of farms. This marks the estimation of further growth in the market due to the advancement in biotechnological research.
The major growth opportunity for the market is the increasing adoption of pet animals and also the rise in the number of pet lovers. Veterinary vaccines play important role in preventing infectious diseases in animals and this factor is boosting up the demand of the market extensively. In the Asia Pacific, there are increasing incidences of zoonotic diseases where government agencies are taking initial steps in order to control the spread of diseases is fuelling the growth of the market.
In addition, increasing the livestock population is one more factor lavishing the growth of the market. Increasing investments in veterinary hospitals to improve the quality of treatment procedures at low cost is creating chances for the market to grow. Growing demand to increase the productivity of poultry products with great quality is merely to lavish the demand of this market in Asia pacific. The rise in the consumption rate of meat is gearing up the growth of the market. Increasing campaigns to spread awareness in rural areas and to prevent transmission of diseases from animals to humans is spurring the growth of the veterinary vaccines market.
This research report segmented and sub-segmented into the following categories:
By Type: Livestock Vaccines and Companion Vaccines
By Technology: Live Attenuated Vaccines, Inactivated Vaccines, Recombinant Vaccines, Toxoid Vaccines, Subunit Vaccines, DNA Vaccines, and Conjugate Vaccines
By Country: India, China, Japan, Australia, South Korea and Rest of Asia Pacific
Among all, India is holding the highest shares of the market. Rising carious diseases in livestock are bolstering the demand of the market eventually. Also, growing awareness over the availability of different vaccines for various diseases is likely to magnify the demand of the market.
China is also accounted to have significant shares of the market following India. Increasing revenue is one of the best parts for China to have leading shares in this market. A rise in the adoption of companion animals is boosting up the growth rate of the market.
Japan is witnessed in having the fastest growth rate form the past few years and is also expected to have the same growth flow in the coming years. Shifting to DNA vaccines rather than live attenuated vaccines will increase the performance levels in controlling the diseases and this is majorly considered as a growth factor for the market. Also, Adoption of recombinant vaccine solutions is fuelling the growth rate of the market in this country.
Australia is anticipated to have inclined growth rates in the coming years with rising awareness towards safety measurements for animal healthcare.
South Korea is deemed to have significant shares in the coming years by increasing investments from private and public organizations.
Prominent companies playing an active role in the Asia-Pacific Veterinary Vaccines Market are:
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2.2 Analysis Design
2.3 Research Phases
2.3.1 Secondary Research
2.3.2 Primary Research
2.3.3 Econometric Modelling
2.3.4 Expert Validation
2.4 Study Timeline
3.1 Executive Summary
3.2 Key Inferences
3.3 New Developments
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5.1 By Type
5.1.1 Livestock vaccines
5.1.2 Companion vaccines
5.2.1 Live attenuated vaccines
5.2.2 Inactivated vaccines
5.2.3 Recombinant vaccines
5.2.4 Toxoid vaccines
5.2.5 Subunit vaccines
5.2.6 DNA vaccines
5.2.7 Conjugate vaccines
6.5 South Korea
7.1 PESTLE analysis
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.1 Bayer Healthcare AG
8.1.2 Product Analysis
8.1.3 Strategic Evaluation and Operations
8.1.4 Financial analysis
8.1.5 Legal issues
8.1.6 Recent Developments
8.1.7 SWOT analysis
8.1.8 Analyst View
8.2 Bioniche Animal Health Canada
8.3 Sanofi Animal Health Inc.
8.4 Biogenesis Bago SA
8.5 Heska Corporation
8.6 Indian Immunologicals Ltd.
8.7 Boehringer Ingelheim GmbH
8.8 Novartis Animal Health, Inc.
8.9 Merck & Co. Inc.
8.10 Protein Sciences
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10.1 Market Outlook
10.2 Investment Opportunities